(Q37047547)

17 August 2017

1 reference

title

Human cholesterol metabolism and therapeutic molecules (English)

1 reference

17 August 2017

V Charlton-Menys

1

1 reference

PubMed ID

18165431

17 August 2017

P N Durrington

series ordinal

2

1 reference

17 August 2017

1 January 2008

1 reference

17 August 2017

Experimental Physiology

1 reference

17 August 2017

93

1 reference

17 August 2017

1

1 reference

17 August 2017

27-42

1 reference

Antisense apolipoprotein B therapy: where do we stand?

17 August 2017

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The paradox of dysfunctional high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Cord blood lipoproteins and prenatal influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

CETP gene variation: relation to lipid parameters and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Niemann-Pick type C disease and intracellular cholesterol trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Paraoxonase and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Safety considerations with gastrointestinally active lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The mechanism for apo-B mRNA editing is deamination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Lipid levels and the risk of ischemic stroke in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

ATP-binding cassette, subfamily G (ABCG family).

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Lipoproteins in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Intestinal cholesterol transport proteins: an update and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

HDL cholesterol: physiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Intracellular assembly of VLDL: two major steps in separate cell compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Familial hypobetalipoproteinemia: genetics and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Two 7 alpha-hydroxylase enzymes in bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Comparison of statins in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Regulation of intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2006.035147

10.1113/EXPPHYSIOL.2006.035147

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18165431